REKOVER study protocol: a pRospective patient treatment rEgistry of tramadol and dexKetoprofen trometamol oral fixed-dose combination (SKUDEXA) in mOderate to seVere acutE pain in Real-world setting in Asia
BMJ Open · 2024
DOI: 10.1136/bmjopen-2023-080620 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift BMJ Open, 2024. Verfasst von Kok Yuen Ho und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Pain Clinic, Mount Alvernia Medical Centre, Singapore hokokyuen@gmail.com. Hauptthemen laut MEDLINE: Tramadol, Acute Pain, Tromethamine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: A. Menarini Asia-Pacific Holdings Pte Ltd.
Abstract (Originalsprache)
Introduction Satisfactory management of acute pain remains a major medical challenge despite the availability of multiple therapeutic options including the fixed-dose combination (FDC) drugs. Tramadol and dexketoprofen trometamol (TRAM/DKP) 75/25 mg FDC was launched in 2018 in Asia and is widely used in the management of moderate to severe acute pain. There are limited data on its effectiveness and safety in Asian patients, and therefore, a need to better understand its usage patterns in clinical practice. We aim to understand the usage pattern of TRAM/DKP FDC, its effectiveness and tolerability in patients with moderate to severe acute pain in Asia. Methods and analysis REKOVER is a phase-IV, multicountry, multicentre, prospective, real-world observational study. A total of 750 postsurgical and non-surgical patients (male and female, aged 18–80 years) will be recruited from 13 tertiary-care hospitals (15 sites) in Singapore, Thailand, the Philippines and Malaysia. All patients prescribed with TRAM/DKP FDC and willing to participate in the study will be enrolled. The recruitment duration for each site will be 6 months. The severity of pain will be collected using Numeric Pain Rating Scale through the treatment period from day 1 to day 5, while satisfaction with the treatment will be evaluated using Patient Global Evaluation Scale at the end of treatment. Any adverse event reported during the study duration will be recorded for safety analysis (up to day 6). The study data will be entered into the ClaimIt portal and mobile application (app) (ObvioHealth, USA). All the inpatient data will be entered into the portal by the study site and for outpatient it will be done by patients through an app. Ethics and dissemination The study has been approved by the local ethics committee from each study sites in Singapore, Thailand, the Philippines and Malaysia. Findings will be disseminated through local and global conference presentations, publications in peer-reviewed scientific journals and continuing medical education.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Pain Clinic, Mount Alvernia Medical Centre, Singapore hokokyuen@gmail.com.
- Medical Affairs, A Menarini Asia Pacific Holdings Pte Ltd, Singapore.
- Department of Orthopedics, The Medical City, Pasig City, Philippines.
- Sports Medicine Institute, Cardinal Santos Medical Center, San Juan, Philippines.
- Department of General Surgery, The Medical City, Pasig City, Philippines.
- Pain Care Center, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
ORCID-Profile: Bibek Gyanwali
Förderung
- A. Menarini Asia-Pacific Holdings Pte Ltd
Zitieren
APA
Ho, K. Y., Gyanwali, B., Dimayuga, C., Eufemio, E. M., Bernardo, E., Raju, G., Chong, K. W., Waithayayothin, K., Ona, L., Castro, M. A. L., Sawaddiruk, P., Salvador, R. C., Roohi, S. A., Tangwiwat, S., Wilairatana, V., Oon, Z. H., Gupta, A., & Nagrale, D. (2024). REKOVER study protocol: a pRospective patient treatment rEgistry of tramadol and dexKetoprofen trometamol oral fixed-dose combination (SKUDEXA) in mOderate to seVere acutE pain in Real-world setting in Asia. BMJ Open. https://doi.org/10.1136/bmjopen-2023-080620
Vancouver
Ho KY, Gyanwali B, Dimayuga C, Eufemio EM, Bernardo E, Raju G, et al. REKOVER study protocol: a pRospective patient treatment rEgistry of tramadol and dexKetoprofen trometamol oral fixed-dose combination (SKUDEXA) in mOderate to seVere acutE pain in Real-world setting in Asia. BMJ Open. 2024. doi:10.1136/bmjopen-2023-080620
BibTeX
@article{Ho2024,
author = {Ho, Kok Yuen and Gyanwali, Bibek and Dimayuga, Cesar and Eufemio, Edgar Michael and Bernardo, Edwin and Raju, Gopinathan and Chong, Keen Wai and Waithayayothin, Kritsadakorn and Ona, Leonardo and Castro, Marc Anthony L and Sawaddiruk, Passakorn and Salvador, Roehl C and Roohi, Sharifah Ahmad and Tangwiwat, Suwimon and Wilairatana, Vajara and Oon, Zhi Hao and Gupta, Ankur and Nagrale, Dinesh},
title = {REKOVER study protocol: a pRospective patient treatment rEgistry of tramadol and dexKetoprofen trometamol oral fixed-dose combination (SKUDEXA) in mOderate to seVere acutE pain in Real-world setting in Asia},
journal = {BMJ Open},
year = {2024},
doi = {10.1136/bmjopen-2023-080620}
}
EUVIMED